TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Known or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; pheochromocytoma. Supporting evidence may include MRI, CT, biochemical markers, and or pathology report.~* Age \> 1.~* Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group (ECOG) / World Health Organization (WHO) equivalent).~* Not pregnant. A negative serum pregnancy test is required for all female subjects with childbearing potential.~* Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~* Hepatic enzymes 5 times greater than the upper limits of normal, serum creatinine \> 3.0 mg/dL (270 Micromole per liter (uM/L).~* Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET /CT scanner due to BMI~* Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.); although at Mission Bay Hospital pediatric patients may be sedated per clinical protocol.~* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.).~* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.~* Recognized concurrent active infection Previous systemic or radiation treatment for another cancer of any type within the last 2 months.~* Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68 DOTA-TOC PET/CT (Type: EXPERIMENTAL): Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Liver transplant recipients with at least 3 years of post-operative follow-up in whom gene expression pattern changed from non-tolerant to tolerant under sirolimus treatment.~2. Feasibility of performing very frequent (every 2-3 weeks) clinical follow-up visits.~3. No history of graft rejection during the previous 12 months.~4. Basal liver biopsy without signs of rejection~5. Stability of liver graft function, defined as: a) normal liver function tests (AST, ALT, ALP, GGT) during at least 6 months; or alternatively b) minor alterations in liver function tests that have not changed over the previous 6 months (AST/ALT \< 2 fold normal levels; ALP \< 1.5 fold normal levels; GGT \< 2 fold normal levels; bilirubin \< 2 mg/dL).~6. Presence of peripheral blood biomarkers of high likelihood of tolerance as defined by: a) transcriptional pattern associated with tolerance regardless of the basal immunosuppressive regimen; and/or b) 2-fold increase in Treg frequency in patients who have discontinued calcineurin inhibitors in the 12 months prior to inclusion.~7. Signature of informed consent.~Exclusion Criteria:~1. Requirement of immunosuppressive treatment for an indication different to liver transplantation.~2. Documented human immunodeficiency virus (HIV) infection.~3. Liver-Kidney transplant recipients.~4. History of liver autoimmune disease (autoimmune hepatitis, primary liver cirrhosis, primary sclerosing cholangitis)~5. Active hepatitis C virus infection as defined by positive serum HCV-RNA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Weaning patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REstart or STop Antithrombotic Randomised Trial in France

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient age ≥18 years.~* Spontaneous intracerebral hemorrhage confirmed by imaging~* Patient had been taken antithrombotic drug(s) for the prevention of vaso-occlusive disease for at least 1 week before ICH onset~* Randomisation more than 24 hours after ICH onset.~* Patient and their doctor are uncertain about whether to start or avoid antiplatelet drugs.~* Brain imaging that first diagnosed the ICH is available. Participant or representative consent.~Exclusion Criteria:~* intracerebral hemorrhage associated with : a vascular malformation (AVM, arterial aneurysm, cavernoma); a secondary hemorrhagic infarction; a cerebral venous thrombosis; a tumor~* Patients with a formal indication of restarting oral anticoagulants despite the ICH (eg mechanical heart valves or pulmonary embolism under 6 months)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Start antiplatelet drug(s) (Type: EXPERIMENTAL): If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
- Avoid antiplatelet drug(s) (Type: NO_INTERVENTION): If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be male or female, aged 6 - 12 years with ADHD.~2. Subject must (a) be taking methylphenidate, amphetamine, or atomoxetine for treatment of ADHD with parent or subject concerns of inadequate efficacy or intolerable side effects, or (b) free of any other medication used to treat ADHD for at least 30 days at the time of the initial sleep study.~3. Subject must have repeated difficulty with sleep initiation or persistence despite attempts at adequate sleep hygiene.~4. Subject must be able to swallow tablets.~Exclusion Criteria:~1. Subject or parent/LAR is unable or unwilling to discontinue present medications used to treat ADHD.~2. Subject has a body mass index \< 5th percentile for age, using the Centers for Disease Control standards reported in 2000.~3. Subject has a body weight \> 176 pounds.~4. Subject has a diagnosis of Autism or Autism Spectrum Disorder.~5. Subject has other serious psychiatric diagnoses.~6. Subject has a medical condition that may require treatment with an unapproved medication, that may cause a safety concern, or that may confound outcome results~7. Subject has an excessive caffeine intake (greater than 2.5 mg/kg/d).~8. Subject has a prior problem with clonidine or guanfacine.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Guanfacine Extended-Release Tablets (Type: EXPERIMENTAL): Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
- Placebo comparator (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Abdominal aortic surgery~* Supra and infrainguinal peripheral vascular bypass surgery~* Below knee amputations~* Above knee amputations~* Diabetics and nondiabetics~* American Society of Anesthesiologists (ASA) I-III~Exclusion Criteria:~* Brittle diabetics~* ASA 1V,V~* Second surgery in same admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CII, Continuous Insulin Infusion (Type: EXPERIMENTAL): Continuous intravenous insulin infusion to control glucose to \<150 mg/dL in patients undergoing open peripheral vascular bypass surgery
- IIB, Intermittent insulin boluses (Type: ACTIVE_COMPARATOR): Intermittent intravenous insulin insulin boluses to a blood glucose target of \<150mg/dL in patients undergoing peripheral vascular bypass surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic~Exclusion Criteria:~* Pregnancy~* Bladder cancer~* Symptomatic urinary infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to inclusion.~* Chronic heart failure will be defined as requiring treatment for a minimum of 30 days prior to current admission, NYHA Class III or IV at the time of hospitalization, and left ventricular ejection fraction less than 40% within one year or evidence of heart failure with preserved ejection fraction and evidence of diastolic dysfunction on echocardiogram.~* Admitted with clinical decompensated heart failure based on history, physical exam, and parameters indicating extracellular volume expansion such as including JVP ≥ 8 cm of water and 1+ or greater peripheral edema~* Is able to be dosed with study medication within six (6) hours of first dose of IV diuretics~Exclusion Criteria:~* Baseline severe hypotension (Mean arterial pressure \< 55 mm Hg)~* Creatinine clearance less than 20 ml/min or creatinine greater than 2.5 mg/dl.~* Serum sodium less than 128 meq/L.~* Serum Potassium \< 3.0 meq/L.~* Known adverse reaction to metolazone~* Inability to take oral medications~* Severe Aortic Stenosis (AVA \< 0.8cm2)~* History of Hypertrophic obstructive cardiomyopathy~* Metastatic Carcinoma per history~* Severe COPD, FEV \< 1L~* Severe dyspnea requiring prolonged CPAP,BIPAP or intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Placebo (Type: PLACEBO_COMPARATOR): This group will receive all standard heart failure therapy and placebo pill.
- Experimental: Metolazone (Type: ACTIVE_COMPARATOR): This group will receive all standard heart failure therapy with addition of metolazone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Ventilation and Physical Activity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* restrictive pulmonary function test AND~* symptoms of nocturnal alveolar hypoventilation or~* increased daytime pressure of arterial CO2 (PaCO2) (\>45 mmHg) or~* \>= 10 mmHg increase in PaCO2 during sleep in comparison to a normal awake supine value~Exclusion Criteria:~* patients \< 16 years~* severe cardiac arrythmias or conduction disturbances~* severe mental disturbances~* amyotrophic lateral sclerosis~* total wheelchair-dependent patients

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with RLD initiating NIV (Type: OTHER): Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fractional CO2 Laser Treatment of Hypertrophic Scars

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children (age 1- 17) who present with hypertrophic scarring following an acute injury or burn, with stable closed scars at least 3 months post wound closure.~Exclusion Criteria:~* Outside of age limits described above.~* Contraindications to general anesthesia.~* Open wounds in scars.~* Active infection.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Control half of scar (Type: NO_INTERVENTION): one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
- Laser treatment half of scar (Type: EXPERIMENTAL): The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PAIR Study-PAP And IOP Relationship: Study 1

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>40 years~* Able to give informed consent and attend for the study visit.~Exclusion Criteria:~* Previous surgical treatment for glaucoma~* Current or recent (within 4 weeks) CPAP or non-invasive ventilation (NIV) use~* History of face mask intolerance~* Any facial lesion preventing safe CPAP mask application~* Allergy to silicone~* Any contraindications to rebound tonometry, including: corneal scarring, microphthalmos, buphthalmos, nystagmus, keratoconus, abnormal central corneal thickness, corneal ectasia, active corneal infection, , and corneal dystrophies.~* Concomitant eye diseases known to affect IOP, including: treated wet age related macular degeneration (ARMD), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), uveitis and diabetic retinopathy.~* Significant lung disease (including previous pneumothorax, previous or current respiratory failure, severe Chronic Obstructive Pulmonary Disease (COPD), bullous lung disease, difficult to control asthma, acute chest infection)~* Significant heart disease (including heart failure, unstable arrhythmias, pulmonary hypertension)~* Untreated upper gastro-intestinal obstruction~* Acute infectious diseases~* Known or suspected pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treated glaucoma (Type: EXPERIMENTAL): POAG patients established on treatment
- Untreated (Type: EXPERIMENTAL): Newly diagnosed treatment naïve POAG patients
- Control (Type: ACTIVE_COMPARATOR): Control subjects without glaucoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiological Study of CSA in Adults With pLVEF

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male patient~* Age ≥18 years and ≤85 years~* With preserved LVEF heart failure (defined as LVEF ≥ 45% on ultrasound, MRI or isotopic ventriculography)~* Central SAS Group: Central to severe sleep apnea syndrome, defined by an apnea-hypopnoea index (IAH) greater than 15 per hour, of which at least 30% are central events;~* Obstructive SAS group: Moderate to severe obstructive sleep apnea syndrome, defined by an apnea-hypopnoea index (IAH) greater than 15 per hour, with a central event proportion of less than 30%~* Group snoring: absence of sleep apnea syndrome or mild sleep apnea syndrome (IAH \<15 / h) in polysomnography, and presence of snoring on at least 30% of the night of recording.~* Free, informed and written consent~* Patient affiliated to a social security scheme (beneficiary or beneficiary)~Exclusion Criteria:~* Impossibility of giving the subject informed information~* Participation in a research protocol involving the human person in the previous months if an exclusion directive is given in this protocol~* Use of respiratory or sedative depressant drugs, systemic corticosteroid therapy~* Impaired systolic function (defined by LVEF \<45% in ultrasound, MRI or isotopic ventriculography)~* Unstable cardiovascular disease (cardiovascular event of less than one month)~* Recent surgery of the ENT sphere (less than 6 months)~* Central neurological pathology known~* Known, severe respiratory pathology (severity left to the investigator's discretion)~* Renal insufficiency (creatinine clearance \<60 mL / min) or severe hepatic impairment~* Primary or secondary hemostasis disorder~* Patient on anticoagulant (antivitamin K, direct oral anticoagulant, heparin and related). Antiplatelet agents are allowed.~* Psychiatric pathology according to DSM-V criteria, unbalanced~* Pulsed saturation with oxyhemoglobin \<88% at rest, on awakening~* Allergy to lidocaine~* Patient under tutorship or curatorship~* Failure to perform a prior medical examination~* Tympanic perforation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Central SAS cases (Type: OTHER): Patients with central apnea
- Obstructive SAS controls (Type: OTHER): Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
- Snorers controls (Type: OTHER): Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas \<15 / h)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for patients :~* Patients with nasosinus polyposis requiring nasosinus surgery~* Patient affiliated or entitled to a social security~* signed consent~Inclusion Criteria for control group :~* Patients with an indication for septoplasty~* Patient affiliated or entitled to a social security~* signed consent~Exclusion Criteria for patients :~* Patients with nasosinus polyposis secondary to another disease~* Patients with hyposmia or anosmia prior to naso-sinus polyposis~* Patients with diagnosed neurodegenerative disease~* Patients who are mentally or physically unable to perform olfactory tests~* Patients on anti-TNF-alpha therapy, long-term oral corticosteroid therapy, or other immunomodulatory therapy.~Exclusion Criteria for control group :~* Patients with nasosinus polyposis~* Patients with chronic rhino-sinusitis~* Patients with hyposmia or anosmia~* Patients with diagnosed neurodegenerative disease~* Patients who are mentally or physically unable to perform olfactory tests~* Patients on anti-TNF-alpha therapy, long-term oral corticosteroid therapy, or other immunomodulatory therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with chronic rhinosinusitis with nasal polyps (Type: EXPERIMENTAL): None
- Patients with an indication for septoplasty = control group (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility